Diabetes initiative and the global fight against the urban diabetes epidemic. These two major metropolitan centres are the first Chinese cites to become part of the global partnership programme, which was initiated in Mexico City in March 2014, followed by Copenhagen in Europe and Houston in the United States last week.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7377451-novo-nordisk-shanghai-diabetes/
With gout incidence on the rise, an increasing number of medical professionals, across multiple fields of practice, will continue to be exposed to patients who suffer from gout and are seeking an accurate diagnosis and treatment. However, despite the availability of the “Guidelines for the Management of Gout” by the American College of Rheumatology (ACR), there are many inconsistencies in how gout is diagnosed, treated and discussed by medical professionals. Conflicting messages and treatment recommendations can contribute to confusion, and even lack of compliance, on behalf of the patient – particularly when gout is connected with comorbid conditions, such as kidney disease, heart disease or diabetes.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7362551-gout-uric-acid-education-society-guaes-roundtable-consensus-paper/
In support of American Diabetes Month®, Colgate Total kicked-off the “Small Steps Make a Big Difference” campaign to help raise awareness surrounding the often overlooked association between oral health and diabetes.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7332551-colgate-total-american-diabetes-association-small-steps-make-a-big-difference-campaign/
http://blog.topdentistsonline.com/type-2-diabetes-2/ Receiving the diagnosis of type 2 diabetes can be stressful. Some feel like it’s a death sentence. Others may be afraid of the health complications of diabetes. Some feel denial, guilt or anger. These different emotions are part of coming to terms with a life changing diagnosis. But the important thing to remember is that you are not alone.
http://blog.topdentistsonline.com/type-2-diabetes/ Did you know that 25.8 million people suffer from diabetes? In this video you will learn more about Prediabetes, Type 1 Diabetes, and Type 2 Diabetes. This includes symptoms, complications, and treatments.
ACCU-CHEK Aviva Expert offers people with diabetes a new and easy way to simplify complex calculations to deliver precise insulin dosing advice.
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the ACCU-CHEK® Aviva Expert system, the first and only blood glucose meter system with a built-in insulin calculator to be approved by the U.S. Food and Drug Administration (FDA), is now available by prescription. The device represents a significant advancement in blood glucose meter technology for people with diabetes who take multiple daily insulin injections. The meter’s integrated bolus calculator provides easy-to-use and reliable dose recommendations based on automated calculations, eliminating the need for manual dosing calculations and estimations.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7322751-roche-accu-chek-aviva-expert-blood-glucose-meter-now-available/
Today, WebMD Health Corp. (NASDAQ: WBMD) launched WebMD Healthy Target, an integrated health improvement program that uses biometric device data from activity trackers, wireless scales and glucose meters to deliver tailored, physician-reviewed, contextually relevant content and motivational tips to individuals looking to develop sustainable health-conscious habits. WebMD Healthy Target will provide valuable assistance to individuals looking to manage chronic conditions like Type 2 diabetes and obesity, as well as to a broader audience interested in achieving their fitness goals or more generally living a healthier lifestyle.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/70402510-webmd-launches-health-improvement-program-for-iphone/
Novo Nordisk today announces the launch of ‘Cities Changing Diabetes’, an ambitious new partnership programme to fight the urban diabetes challenge. The ‘Cities Changing Diabetes’ programme will first be launched in Mexico City with other cities in North America, Europe and Asia soon to follow.
“The global diabetes epidemic is an emergency in slow motion,
Se pone en marcha el primer estudio integral a largo plazo que compara diferentes medicaciones para el tratamiento de la diabetes tipo 2 a escala nacional. El estudio GRADE (Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness - Estrategias para la reducción de la glucemia en la diabetes: una comparativa de la eficacia) comparará los efectos beneficiosos y riesgos a largo plazo de cuatro fármacos ampliamente utilizados en el tratamiento de la diabetes, en combinación con metformina, la medicación de primera línea más frecuente para tratar la diabetes tipo 2. El estudio GRADE está buscando voluntarios latinos.
Para ver el Multimedia News Release, vaya a http://www.multivu.com/mnr/65066-nih-grade-study-on-type-2-diabetes-medication-seeks-latino-volunteers
The first comprehensive long-term study comparing different medications for type 2 diabetes is launching nationwide. The GRADE (Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness) Study will compare the long-term benefits and risks of four widely used diabetes drugs in combination with metformin, the most common first-line medication for treating type 2 diabetes.
To view Multimedia News Release, go to http://www.multivu.com/mnr/64578-grade-glycemia-reduction-approaches-in-diabetes-comparative-effectiveness
Results from the global Diabetes Attitudes, Wishes and Needs 2 study (DAWN2™) presented today at a symposium during the World Diabetes Congress of the International Diabetes Federation (IDF), show that only 29% of people with diabetes report that their healthcare team ask for their input when making their treatment plans. Furthermore, only 33% said they were encouraged by their healthcare professional to ask questions in the consultation.
To view Multimedia News Release, go to http://www.multivu.com/mnr/64152-novo-nordisk-diabetes-report-doctor-treatment
Data presented today at the World Diabetes Congress of the International Diabetes Federation (IDF) show that adults with type 2 diabetes achieved improved glycaemic control, significantly lower rates of overall and nocturnal confirmed hypoglycaemia for the full trial period, and a significantly lower rate of severe hypoglycaemia during the maintenance period (defined as week 16 onwards) with Ryzodeg® compared to biphasic insulin aspart 30, both administered twice-daily1.
Ryzodeg® is the first combination of two distinct insulin analogues, Tresiba® (insulin degludec), the once-daily basal insulin with an ultra-long duration of action, and the well-established mealtime insulin NovoRapid® (insulin aspart), in the ratio of 70% and 30%, in one pen for people with type 2 diabetes2-4.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/64158-ryzodeg-improved-glycaemic-control
